Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Cyclin dependent kinase 7 (CDK7) is a master regulatory kinase that drives cell cycle progression and stimulates expression of oncogenes in a myriad of cancers. Inhibitors of CDK7 (CDK7i) are currently in clinical trials; however, as with many cancer therapies, patients will most likely experience recurrent disease due to acquired resistance. Identifying targets underlying CDK7i resistance will facilitate prospective development of new therapies that can circumvent such resistance.
Cell Fate Decisions Benjamin L. Bryson, Ilaria Tamagno, Sarah E. Taylor, Neetha Parameswaran, Noah M. Chernosky, Nikhila Balasubramaniam and Mark W. Jackson DOI: 10.1158/1541-7786.MCR-19-1181 Published April 2021 This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
